Encephalitis

Encephalitis is an acute inflammation of the brain.

What is Encephalitis?

Encephalitis is a relatively rare condition that causes inflammation of the brain. Initial symptoms usually include high temperature, headache and joint pain but as the infection progresses, more dangerous symptoms may start to develop and include the following...

What Can Aedes Mosquitoes Transmit?

Autoimmune Encephalitis Classification

Autoimmune encephalitis

Autoimmune encephalitis Diagnosis

Autoimmune Encephalitis Pathophysiology

Autoimmune Encephalitis Treatment

What is Anti-NMDA Receptor Encephalitis?

Diagnosis of Anti-NMDA Receptor Encephalitis

Risk Factors for Anti-NMDA Receptor Encephalitis

Treatment and Prognosis of Anti-NMDA Receptor Encephalitis

Latest Encephalitis News and Research

Breakthrough study maps critical structure of Nipah virus polymerase

Scientists at Harvard Medical School and Boston University Chobanian & Avedisian School of Medicine have mapped a critical component of the Nipah virus, a highly lethal bat-borne pathogen that has caused outbreaks in humans almost every year since it was identified in 1999.

20 Jan 2025

Review highlights the pathogenesis and clinical spectrum of Nipah virus infection

Nipah virus (NiV), a zoonotic paramyxovirus with significant human health implications, has garnered considerable attention due to its high fatality rates and potential for human-to-human transmission, posing a global public health threat.

15 Jan 2025

T cells can completely prevent viral infections in humans

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells-white blood cells that can destroy harmful pathogens-can completely prevent viral infection, to an extent previously thought only possible due to neutralizing antibodies.

10 Jan 2025

Aston University researcher receives major grant to investigate autoimmune encephalitis

Dr. Sukhvir Wright at Aston University Institute for Health and Neurodevelopment (IHN), and honorary consultant neurologist at Birmingham Children's Hospital (BCH), has been awarded a £3.4m Career Development Award from Wellcome to research autoimmune encephalitis (AE), an inflammatory brain condition, in children.

15 Dec 2024

Measles outbreaks increase worldwide with inadequate immunization coverage

Worldwide, there were an estimated 10.3 million cases of measles in 2023, a 20% increase from 2022, according to new estimates from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). Inadequate immunization coverage globally is driving the surge in cases.

14 Nov 2024

Metagenomic sequencing improves detection of rare pathogens in CNS infections

New research shows that metagenomic next-generation sequencing (mNGS) over seven years increased pathogen detection in challenging CNS infections, identifying rare and unexpected microbes often missed by standard testing.

13 Nov 2024

Next-generation metagenomic sequencing test quickly detects any kind of pathogen

Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind of pathogen.

12 Nov 2024

Understanding the role of neuroimmune cells in brain health and disease

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.

6 Nov 2024

How a ketogenic diet could reduce autoimmune disease severity through host-microbiome interactions

This study uncovers the ketogenic diet's effects on the microbiome, revealing its potential to mitigate autoimmune diseases through metabolic pathways.

6 Nov 2024

Critical protein linked to spillover potential of animal viruses

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

1 Nov 2024

A review of clinical features, diagnosis, and management of Mpox

A comprehensive review in JAMA outlines monkeypox's clinical presentation and management, stressing the need for increased surveillance and vaccination efforts.

17 Oct 2024

Increasing cases of mosquito-borne diseases call for greater awareness

The hospitalization last summer of Dr. Anthony Fauci, former head of the National Institute of Allergy and Infectious Diseases, with West Nile virus – and his account of it this week in the New York Times – have helped raise public awareness of the dangers of mosquito borne-illness, which can range from Zika and malaria to dengue and West Nile virus.

8 Oct 2024

How viral persistence and immune dysfunction drive long COVID

Study explores the biological drivers and mechanisms of long COVID, shedding light on its epidemiology and potential therapeutic interventions. It emphasizes the role of viral persistence, immune dysfunction, and coagulation in the development of this condition.

29 Sep 2024

NIH funds new research to combat emerging viruses

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

14 Sep 2024

New research network focuses on high-priority viruses

The National Institutes of Health (NIH) has established a pandemic preparedness research network to conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies. Currently, many of the diseases caused by these pathogens have no available vaccines or therapeutics, and investing in this research is key to preparing for potential public health crises - both in the United States and around the world. NIH's National Institute of Allergy and Infectious Diseases (NIAID) expects to commit approximately $100 million per year to fund the program, pending the availability of funds.

14 Sep 2024